Working PaperWorking Paper Series
Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010–2019
Amid debates over costs—and profits—from a coronavirus vaccine, a new study shows that taxpayers have been footing the bill for every new drug approved between 2010 and 2019
Working PaperWorking Paper
How “Maximizing Shareholder Value” Minimized the Strategic National Stockpile: The $5.3 Trillion Question for Pandemic Preparedness Raised by the Ventilator Fiasco
The success of projects for pandemic preparedness and response depends on the strength of government-business collaborations.